


Participant Flow**Baseline Characteristics**

Parameter		Statistic	Overall (N=6)
Age (yrs)		Mean	30.2
		SD	3.37
Height (m)		Mean	1.752
		SD	0.0924
Weight (kg)		Mean	79.02
		SD	12.362
BMI (kg/m ²)		Mean	25.67
		SD	3.018
Race:	Caucasian	n (%)	5 (83.3)
	Other	n (%)	1 (16.7)
Gender:	Male	n (%)	6 (100.0)
	Female	n (%)	0 (0.0)

Outcome Measures**Table S2: Summary of Derived Exhaled Breath Pharmacokinetic Parameters – Propylene Glycol**

Period/ Regimen	GeoMean $C_{\max}$ (ppb)	Median $T_{\max}$ (min)	GeoMean AUC_{0-t} (min*ppb)
Including product use (0-5 min)			
PERIOD 1: Inhalation (N=6)	3180	3.00	14400
	(3090)		(7150)
PERIOD 3: Inhalation (N=6)	8710	3.00	20000
	(8560)		(18600)
PERIOD 4: Mouth-holding (N=6)	717000	3.00	1330000
	(714000)		(1260000)
Excluding product use (0-5 min)			
PERIOD 1: Inhalation (N=6)*	132	5.00	5400
	(80.5)		(637)
PERIOD 2: Mouth-holding (N=6)*	96.6	24.2	5430
	(52.9)		(675)

Note: baseline adjusted values presented in brackets

PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4).

*PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min).

Table S3: Summary of Derived Exhaled Breath Pharmacokinetic Parameters – Vegetable Glycerol

Period/ Regimen	GeoMean $C_{\max}$ (ppb)	Median $T_{\max}$ (min)	GeoMean AUC_{0-t} (min*ppb)	
Including product use (0-5 min)				
PERIOD 1: Inhalation (N=6)	52800	2.75	108000	
	(52800)		(107000)	
PERIOD 3: Inhalation (N=6)	240000	3.25	432000	
	(239000)		(428000)	
PERIOD 4: Mouth-holding (N=6)	1920000	3.25	2460000	
	(192000)		(2360000)	
Excluding product use (0-5 min)				
PERIOD 1: Inhalation (N=6)*	662	5.00	4160	
	(655)		(3390)	
PERIOD 2: Mouth-holding (N=6)*	30.1	5.67	1190	
	(19.9)		(262)	

Note: baseline adjusted values presented in brackets

PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4).

*PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min).

Table S4: Summary of Derived Exhaled Breath Pharmacokinetic Parameters – Nicotine

Period/ Regimen	GeoMean $C_{\max}$ (ppb)	Median $T_{\max}$ (min)	GeoMean AUC_{0-t} (min*ppb)
Including product use (0-5 min)			
PERIOD 1: Inhalation (N=6)	1.71	0.500	29.4
	(1.43)		(5.70)
PERIOD 3: Inhalation (N=6)	1.34	2.50	4.95
	(0.947)		(1.84)
PERIOD 4: Mouth-holding (N=6)	286	4.00	815
	(236)		(495)
Excluding product use (0-5 min)			
PERIOD 1: Inhalation (N=6)*	0.558	46.5	26.8
	(0.293)		(3.65)
PERIOD 2: Mouth-holding (N=6)*	0.285	35.3	19.0
	(0.115)		(1.34)

Note: baseline adjusted values presented in brackets

PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4).

*PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min).

Summary of Derived Exhaled Breath VOC Pharmacokinetic Parameters including Product Use Concentrations – Ethanol (ppb) (PK Set)

Ethanol (ppb)					
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)	
PERIOD 1: Inhalation (N=6)	n	6	6	6	
	Mean	380	1.50	8830	
	SD	190	1.30	5130	
	CV%	49.8	86.9	58.0	
	Min	127	0.00	2260	
	Median	363	1.50	9530	
	Max	596	3.00	14600	
	Geo. Mean	334	N/A	7200	
PERIOD 1: Inhalation (N=6)* (from the nominal time-points 5 min to 120 min)	n	6	6	6	
	Mean	139	39.3	7750	
	SD	105	45.4	4760	
	CV%	75.5	115.4	61.4	
	Min	32.3	5.00	1850	
	Median	122	27.7	8400	
	Max	286	120	12900	
	Geo. Mean	101	N/A	6100	
PERIOD 2: Mouth-holding (N=6)	n	6	6	6	
	Mean	75.0	52.6	5140	
	SD	33.4	34.0	2130	
	CV%	44.5	64.8	41.5	
	Min	40.6	5.00	2460	
	Median	70.7	50.2	5480	
	Max	125	90.0	7440	
	Geo. Mean	68.9	N/A	4720	

Ethanol (ppb)					
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)	
PERIOD 3: Inhalation (N=6)	n	6	6	6	
	Mean	513	2.83	1800	
	SD	294	1.21	1060	
	CV%	57.2	42.7	58.8	
	Min	216	1.00	858	
	Median	501	3.00	1430	
	Max	932	4.50	3440	
	Geo. Mean	439	N/A	1560	
PERIOD 4: Mouth-holding (N=6)	n	6	6	6	
	Mean	4740	3.33	13000	
	SD	3650	0.876	7800	
	CV%	77.0	26.3	59.9	
	Min	1620	2.00	4570	
	Median	3000	3.25	12300	
	Max	9640	4.50	24400	
	Geo. Mean	3710	N/A	11000	
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4). *PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min). NC = Non-Calculable.					

Summary of Derived Exhaled Breath VOC Pharmacokinetic Parameters including Product Use Concentrations – Phenyl Carbinol (ppb) (PK Set)

Phenyl Carbinol (ppb)				
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)
PERIOD 1: Inhalation (N=6)	n	6	6	6
	Mean	1.36	12.2	93.3
	SD	1.03	23.8	74.9
	CV%	76.0	195.0	80.2
	Min	0.605	0.00	36.9
	Median	0.867	2.25	58.1
	Max	3.18	60.3	221
	Geo. Mean	1.10	N/A	73.2
PERIOD 1: Inhalation (N=6)* (from the nominal time-points 5 min to 120 min)	n	6	6	6
	Mean	1.16	51.8	90.3
	SD	0.829	38.2	72.2
	CV%	71.7	73.7	79.9
	Min	0.458	8.33	35.7
	Median	0.736	45.7	56.2
	Max	2.40	121	213
	Geo. Mean	0.945	N/A	70.9
PERIOD 2: Mouth-holding (N=6)	n	6	6	6
	Mean	1.15	74.2	74.6
	SD	0.863	44.6	48.0
	CV%	75.4	60.1	64.3
	Min	0.506	10.0	33.8
	Median	0.745	71.5	50.7
	Max	2.71	122	153
	Geo. Mean	0.938	N/A	63.8

Phenyl Carbinol (ppb)					
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)	
PERIOD 3: Inhalation (N=6)	n	6	6	6	
	Mean	1.58	1.25	9.68	
	SD	0.654	1.04	5.38	
	CV%	41.5	82.9	55.6	
	Min	0.908	0.00	4.57	
	Median	1.45	1.00	8.32	
	Max	2.57	2.50	20.0	
	Geo. Mean	1.47	N/A	8.70	
PERIOD 4: Mouth-holding (N=6)	n	6	6	6	
	Mean	19.9	4.75	131	
	SD	5.86	3.57	28.7	
	CV%	29.5	75.2	22.0	
	Min	15.1	0.00	106	
	Median	17.3	4.25	122	
	Max	28.4	10.7	180	
	Geo. Mean	19.2	N/A	128	

IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system.

PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4).

*PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min).

NC = Non-Calculable.

Summary of Derived Exhaled Breath VOC Pharmacokinetic Parameters including Product Use Concentrations – Methyl Cyclopentenolone (ppb) (PK Set)

Methyl Cyclopentenolone (ppb)				
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)
PERIOD 1: Inhalation (N=6)	n	6	6	6
	Mean	9.35	1.67	37.2
	SD	13.6	1.83	20.1
	CV%	145.1	110.1	53.9
	Min	0.777	0.00	23.7
	Median	2.36	1.25	31.2
	Max	34.8	4.50	77.5
	Geo. Mean	3.43	N/A	34.1
PERIOD 1: Inhalation (N=6)* (from the nominal time-points 5 min to 120 min)	n	6	6	6
	Mean	0.388	8.22	24.7
	SD	0.0743	2.09	2.58
	CV%	19.1	25.5	10.4
	Min	0.302	5.00	21.5
	Median	0.385	8.84	24.7
	Max	0.519	11.0	28.2
	Geo. Mean	0.383	N/A	24.6
PERIOD 2: Mouth-holding (N=6)	n	6	6	6
	Mean	0.343	45.9	24.1
	SD	0.0661	48.9	1.25
	CV%	19.3	106.5	5.2
	Min	0.296	6.00	21.7
	Median	0.322	24.7	24.6
	Max	0.475	120	25.1
	Geo. Mean	0.338	N/A	24.1

Methyl Cyclopentenolone (ppb)				
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)
PERIOD 3: Inhalation (N=6)	n	6	6	6
	Mean	13.3	2.75	31.4
	SD	14.1	1.60	22.7
	CV%	105.8	58.4	72.2
	Min	2.88	0.00	11.3
	Median	8.85	3.00	20.9
	Max	39.0	4.50	71.5
	Geo. Mean	8.12	N/A	25.9
PERIOD 4: Mouth-holding (N=6)	n	6	6	6
	Mean	348	2.58	1220
	SD	186	1.69	522
	CV%	53.6	65.3	42.7
	Min	103	0.00	542
	Median	306	3.25	1090
	Max	581	4.00	1910
	Geo. Mean	300	N/A	1120
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4). *PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min). NC = Non-Calculable.				

Summary of Derived Exhaled Breath VOC Pharmacokinetic Parameters including Product Use Concentrations – Trimethylpyrazine (ppb) (PK Set)

Trimethylpyrazine (ppb)				
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)
PERIOD 1: Inhalation (N=6)	n	6	6	6
	Mean	4.34	2.25	36.3
	SD	2.57	1.57	8.30
	CV%	59.2	69.9	22.9
	Min	2.27	0.00	27.8
	Median	3.22	3.00	33.9
	Max	8.98	3.50	51.1
	Geo. Mean	3.83	N/A	35.6
PERIOD 1: Inhalation (N=6)* (from the nominal time-points 5 min to 120 min)	n	6	6	6
	Mean	1.33	5.33	25.4
	SD	0.741	0.212	4.11
	CV%	55.5	4.0	16.2
	Min	0.490	5.00	20.0
	Median	1.14	5.33	25.5
	Max	2.64	5.67	31.9
	Geo. Mean	1.17	N/A	25.1
PERIOD 2: Mouth-holding (N=6)	n	6	6	6
	Mean	0.701	6.28	22.2
	SD	0.409	2.82	2.20
	CV%	58.4	44.8	9.9
	Min	0.387	5.00	19.7
	Median	0.591	5.00	22.2
	Max	1.50	12.0	25.9
	Geo. Mean	0.629	N/A	22.1

Trimethylpyrazine (ppb)				
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)
PERIOD 3: Inhalation (N=6)	n	6	6	6
	Mean	3.86	2.42	16.6
	SD	1.11	1.20	5.46
	CV%	28.8	49.7	33.0
	Min	2.30	0.500	8.01
	Median	4.19	2.50	16.9
	Max	5.29	4.00	23.2
	Geo. Mean	3.71	N/A	15.7
PERIOD 4: Mouth-holding (N=6)	n	6	6	6
	Mean	102	3.58	337
	SD	75.7	1.80	198
	CV%	74.5	50.2	58.8
	Min	16.8	0.00	131
	Median	79.3	4.50	262
	Max	204	4.50	594
	Geo. Mean	75.4	N/A	290
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4). *PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min). NC = Non-Calculable.				

Summary of Derived Exhaled Breath VOC Pharmacokinetic Parameters including Product Use Concentrations – Propenyl Guaethol (ppb) (PK Set)

Propenyl Guaethol (ppb)				
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)
PERIOD 1: Inhalation (N=6)	n	6	6	6
	Mean	1.68	1.58	14.8
	SD	2.53	1.59	3.10
	CV%	150.6	100.7	21.0
	Min	0.231	0.00	12.3
	Median	0.417	1.50	14.0
	Max	6.65	3.50	20.8
	Geo. Mean	0.746	N/A	14.5
PERIOD 1: Inhalation (N=6)* (from the nominal time-points 5 min to 120 min)	n	6	6	6
	Mean	0.204	25.9	12.8
	SD	0.0296	33.4	0.726
	CV%	14.5	128.6	5.7
	Min	0.159	5.00	11.6
	Median	0.209	10.7	13.1
	Max	0.237	91.3	13.4
	Geo. Mean	0.202	N/A	12.7
PERIOD 2: Mouth-holding (N=6)	n	6	6	6
	Mean	0.199	30.2	13.1
	SD	0.0288	21.8	1.68
	CV%	14.5	72.3	12.8
	Min	0.175	5.00	11.1
	Median	0.185	26.5	12.7
	Max	0.239	60.7	16.1
	Geo. Mean	0.197	N/A	13.0

Propenyl Guaethol (ppb)					
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)	
PERIOD 3: Inhalation (N=6)	n	6	6	6	
	Mean	1.26	3.00	4.20	
	SD	0.961	1.38	2.04	
	CV%	76.5	45.9	48.6	
	Min	0.461	1.50	1.43	
	Median	0.858	2.75	3.89	
	Max	2.94	5.00	7.53	
	Geo. Mean	1.00	N/A	3.75	
PERIOD 4: Mouth-holding (N=6)	n	6	6	6	
	Mean	45.4	2.83	147	
	SD	27.9	1.44	63.3	
	CV%	61.4	50.7	43.2	
	Min	8.56	0.500	61.8	
	Median	42.8	3.00	135	
	Max	81.1	4.50	230	
	Geo. Mean	36.2	N/A	134	
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4). *PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min). NC = Non-Calculable.					

Summary of Derived Exhaled Breath VOC Pharmacokinetic Parameters including Product Use Concentrations – Theobromine (ppb) (PK Set)

Theobromine (ppb)					
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)	
PERIOD 1: Inhalation (N=6)	n	6	6	6	
	Mean	0.237	17.6	9.69	
	SD	0.118	35.7	1.03	
	CV%	49.9	202.7	10.6	
	Min	0.136	0.00	8.87	
	Median	0.183	2.50	9.32	
	Max	0.402	90.0	11.5	
	Geo. Mean	0.215	N/A	9.64	
PERIOD 1: Inhalation (N=6)* (from the nominal time-points 5 min to 120 min)	n	6	6	6	
	Mean	0.144	52.2	9.24	
	SD	0.0171	44.5	0.861	
	CV%	11.9	85.2	9.3	
	Min	0.128	10.7	8.46	
	Median	0.139	35.8	8.95	
	Max	0.176	121	10.6	
	Geo. Mean	0.143	N/A	9.21	
PERIOD 2: Mouth-holding (N=6)	n	6	6	6	
	Mean	0.148	27.8	9.50	
	SD	0.0215	20.1	0.808	
	CV%	14.5	72.4	8.5	
	Min	0.127	5.00	8.62	
	Median	0.146	25.5	9.46	
	Max	0.185	52.0	10.7	
	Geo. Mean	0.147	N/A	9.47	

Theobromine (ppb)					
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)	
PERIOD 3: Inhalation (N=6)	n	6	6	6	
	Mean	0.487	4.33	2.43	
	SD	0.186	3.46	1.07	
	CV%	38.2	79.8	44.1	
	Min	0.321	1.00	0.536	
	Median	0.436	3.75	2.45	
	Max	0.828	11.0	3.68	
	Geo. Mean	0.462	N/A	2.10	
PERIOD 4: Mouth-holding (N=6)	n	6	6	6	
	Mean	7.08	3.36	45.0	
	SD	1.97	3.18	5.64	
	CV%	27.8	94.6	12.5	
	Min	5.26	0.00	38.2	
	Median	6.60	2.75	44.1	
	Max	10.9	8.00	54.1	
	Geo. Mean	6.89	N/A	44.7	
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4) *PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min). NC = Non-Calculable.					

Summary of Derived Exhaled Breath VOC Pharmacokinetic Parameters including Product Use Concentrations – Vanillin PG Acetal (ppb) (PK Set)

Vanillin PG Acetal (ppb)					
Period/ Regimen	Summary Statistic	C _{max} (ppb)	T _{max} (min)	AUC _{0-t} (min*ppb)	
PERIOD 1: Inhalation (N=6)	n	6	6	6	
	Mean	0.549	2.25	10.9	
	SD	0.679	2.14	1.35	
	CV%	123.7	95.1	12.4	
	Min	0.146	0.00	8.98	
	Median	0.200	2.00	11.1	
	Max	1.85	4.50	12.8	
	Geo. Mean	0.325	N/A	10.8	
PERIOD 1: Inhalation (N=6)* (from the nominal time-points 5 min to 120 min)	n	6	6	6	
	Mean	0.162	25.3	10.2	
	SD	0.0257	10.5	0.996	
	CV%	15.9	41.4	9.7	
	Min	0.144	10.0	8.56	
	Median	0.146	25.3	10.6	
	Max	0.197	40.3	11.3	
	Geo. Mean	0.160	N/A	10.2	
PERIOD 2: Mouth-holding (N=6)	n	6	6	6	
	Mean	0.183	17.6	10.1	
	SD	0.0372	13.9	1.44	
	CV%	20.3	78.7	14.3	
	Min	0.143	5.00	8.90	
	Median	0.189	15.7	9.87	
	Max	0.243	42.0	12.9	
	Geo. Mean	0.180	N/A	10.1	

Vanillin PG Acetal (ppb)				
Period/ Regimen	Summary Statistic	C_{max} (ppb)	T_{max} (min)	AUC_{0-t} (min*ppb)
PERIOD 3: Inhalation (N=6)	n	6	6	6
	Mean	0.607	2.83	2.86
	SD	0.387	1.63	1.20
	CV%	63.8	57.6	42.0
	Min	0.388	0.00	0.559
	Median	0.461	3.25	3.08
	Max	1.38	4.50	4.03
	Geo. Mean	0.539	N/A	2.45
PERIOD 4: Mouth-holding (N=6)	n	6	6	6
	Mean	8.84	6.45	56.8
	SD	2.10	4.18	3.18
	CV%	23.8	64.9	5.6
	Min	7.48	0.00	52.9
	Median	7.63	6.59	57.6
	Max	12.5	11.0	61.3
	Geo. Mean	8.66	N/A	56.7
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 120 min for period 1, from 5 min to 120 min for period 2 and from 0 min to 10 min for periods 3 and 4). *PK parameters derived using concentration-time profiles from immediately post-last puff onwards (i.e., from the nominal time-points 5 min to 120 min). NC = Non-Calculable.				

Summary of Statistical Analysis of Baseline Unadjusted Exhaled Breath $C_{\max}$ and AUC_{0-t} Pharmacokinetic Data: Propylene Glycol (PK Set)

		Geometric LSMean (95% C.I.)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Geometric LSMean Ratio (95% C.I.) Period 3/Period 4	Intra-Subject CV(%) from ANCOVA
$C_{\max}$ (ppb)	6	11000 (1370, 89100)	565000 (70100, 4550000)	0.02 (0.00 - 0.61)	206.2
AUC_{0-t} (min*ppb)	6	28400 (3580, 225000)	939000 (119000, 7440000)	0.03 (0.00 - 0.93)	206.1
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. Results obtained using an ANCOVA with a fixed effect of period, subject as a random effect and baseline concentration as a covariate. Baseline defined as the mean of the pre-IP use concentration values. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4).					

Summary of Statistical Analysis of Baseline Adjusted Exhaled Breath $C_{\max}$ and AUC_{0-t} Pharmacokinetic Data: Propylene Glycol (PK Set)

		Geometric LSMean (95% C.I.)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Geometric LSMean Ratio (95% C.I.) Period 3/Period 4	Intra-Subject CV(%) from ANCOVA
$C_{\max}$ (ppb)	6	10900 (1330, 89300)	561000 (68400, 4600000)	0.02 (0.00 - 0.63)	210.2
AUC_{0-t} (min*ppb)	6	26700 (2940, 243000)	877000 (96400, 7970000)	0.03 (0.00 - 1.18)	237.3
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. Results obtained using an ANCOVA with a fixed effect of period, subject as a random effect and baseline concentration as a covariate. Baseline defined as the mean of the pre-IP use concentration values. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4). Any negative values occurring following baseline-adjustment were set to zero prior to PK parameter derivation.					

Summary of Statistical Analysis of Exhaled Breath $T_{\max}$ Pharmacokinetic Data including Product Use Concentrations: Propylene Glycol (PK Set)

		Median (Min, Max)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Interval Midpoint Estimate of Median Difference (95% C.I. ^[a]) Period 3 vs Period 4	p-Value ^[b]
$T_{\max}$ (min)	6	3.00 (2.00 - 4.50)	3.00 (0.00 - 4.50)	0.75 (-1.50 - 3.00)	0.3750
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4). [a] Confidence interval obtained using Hodges-Lehmann method. [b] p-value obtained using the Wilcoxon Signed-Rank test. Non-Calculable.					

Summary of Statistical Analysis of Baseline Unadjusted Exhaled Breath $C_{\max}$ and AUC_{0-t} Pharmacokinetic Data: Vegetable Glycerol (PK Set)

		Geometric LSMean (95% C.I.)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Geometric LSMean Ratio (95% C.I.) Period 3/Period 4	Intra-Subject CV(%) from ANCOVA
$C_{\max}$ (ppb)	6	367000 (70400, 1920000)	1250000 (240000, 6550000)	0.29 (0.02 - 3.46)	235.3
AUC_{0-t} (min*ppb)	6	705000 (155000, 3200000)	1510000 (332000, 6840000)	0.47 (0.05 - 4.49)	195.4
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. Results obtained using an ANCOVA with a fixed effect of period, subject as a random effect and baseline concentration as a covariate. Baseline defined as the mean of the pre-IP use concentration values. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4).					

Summary of Statistical Analysis of Baseline Adjusted Exhaled Breath $C_{\max}$ and AUC_{0-t} Pharmacokinetic Data: Vegetable Glycerol (PK Set)

		Geometric LSMean (95% C.I.)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Geometric LSMean Ratio (95% C.I.) Period 3/Period 4	Intra-Subject CV(%) from ANCOVA
$C_{\max}$ (ppb)	6	367000 (70200, 1920000)	1250000 (239000, 6530000)	0.29 (0.02 - 3.48)	235.6
AUC_{0-t} (min*ppb)	6	699000 (153000, 3200000)	1450000 (316000, 6630000)	0.48 (0.05 - 4.70)	197.9
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. Results obtained using an ANCOVA with a fixed effect of period, subject as a random effect and baseline concentration as a covariate. Baseline defined as the mean of the pre-IP use concentration values. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4). Any negative values occurring following baseline-adjustment were set to zero prior to PK parameter derivation.					

Summary of Statistical Analysis of Exhaled Breath $T_{\max}$ Pharmacokinetic Data including Product Use Concentrations: Vegetable Glycerol (PK Set)

		Median (Min, Max)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Interval Midpoint Estimate of Median Difference (95% C.I. ^[a]) Period 3 vs Period 4	p-Value ^[b]
$T_{\max}$ (min)	6	3.25 (2.00 - 4.50)	3.25 (2.00 - 4.50)	0.00 (-1.00 - 1.00)	1.0000
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4). [a] Confidence interval obtained using Hodges-Lehmann method. [b] p-value obtained using the Wilcoxon Signed-Rank test. Non-Calculable.					

Summary of Statistical Analysis of Baseline Unadjusted Exhaled Breath $C_{\max}$ and AUC_{0-t} Pharmacokinetic Data: Nicotine (PK Set)

		Geometric LSMean (95% C.I.)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Geometric LSMean Ratio (95% C.I.) Period 3/Period 4	Intra-Subject CV(%) from ANCOVA
$C_{\max}$ (ppb)	6	1.66 (0.173, 15.9)	231 (24.1, 2220)	0.01 (0.00 - 0.23)	494.5
AUC_{0-t} (min*ppb)	6	5.35 (0.872, 32.8)	754 (123, 4630)	0.01 (0.00 - 0.11)	248.9
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. Results obtained using an ANCOVA with a fixed effect of period, subject as a random effect and baseline concentration as a covariate. Baseline defined as the mean of the pre-IP use concentration values. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4). Any negative values occurring following baseline-adjustment were set to zero prior to PK parameter derivation.					

Summary of Statistical Analysis of Baseline Adjusted Exhaled Breath $C_{\max}$ and AUC_{0-t} Pharmacokinetic Data: Nicotine (PK Set)

Parameter	Number in Comparison	Geometric LSMean (95% C.I.)			
		Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Geometric LSMean Ratio (95% C.I.) Period 3/Period 4	Intra-Subject CV(%) from ANCOVA
$C_{\max}$ (ppb)	6	1.20 (0.0933, 15.6)	186 (14.4, 2400)	0.01 (0.00 - 0.33)	786.0
AUC_{0-t} (min*ppb)	6	2.17 (0.176, 26.9)	418 (33.8, 5170)	0.01 (0.00 - 0.22)	621.3
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. Results obtained using an ANCOVA with a fixed effect of period, subject as a random effect and baseline concentration as a covariate. Baseline defined as the mean of the pre-IP use concentration values. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4). Any negative values occurring following baseline-adjustment were set to zero prior to PK parameter derivation.					

Summary of Statistical Analysis of Exhaled Breath $T_{\max}$ Pharmacokinetic Data including Product Use Concentrations: Nicotine (PK Set)

		Median (Min, Max)			
Parameter	Number in Comparison	Period 3: Inhalation (N=6)	Period 4: Mouth-holding (N=6)	Interval Midpoint Estimate of Median Difference (95% C.I. ^[a]) Period 3 vs Period 4	p-Value ^[b]
$T_{\max}$ (min)	6	2.50 (0.00 - 8.00)	4.00 (2.00 - 4.50)	0.00 (-3.50 - 3.50)	0.5625
IP = Logic Compact E-cigarette and Tobacco Flavour pod, nicotine concentration 12 mg/mL using inhalation or mouth-holding regime. During periods 3 and 4, exhalation will be performed via dilution system. PK parameters derived using concentration-time profiles from post-first puff onwards (i.e., from the nominal time-points 0 min to 10 min for periods 3 and 4). [a] Confidence interval obtained using Hodges-Lehmann method. [b] p-value obtained using the Wilcoxon Signed-Rank test. Non-Calculable.					

Summary of Theoretical Consumed Amount of PG, VG and Nicotine (Per Protocol Set)

Compound	Period/Regimen	Theoretical Consumed Amount (mg)					
		n	Mean	SD	Min	Median	Max
PG	Period 1: Inhalation (N=6)	6	18.38	11.175	3.7	19.76	30.5
	Period 2: Mouth-holding (N=6)	6	9.89	9.031	1.0	7.58	25.8
	Period 3: Inhalation (N=6)	6	19.97	10.314	9.7	18.29	39.1
	Period 4: Mouth-holding (N=6)	6	7.99	5.534	3.2	6.65	17.9
VG	Period 1: Inhalation (N=6)	6	18.38	11.175	3.7	19.76	30.5
	Period 2: Mouth-holding (N=6)	6	9.89	9.031	1.0	7.58	25.8
	Period 3: Inhalation (N=6)	6	19.97	10.314	9.7	18.29	39.1
	Period 4: Mouth-holding (N=6)	6	7.99	5.534	3.2	6.65	17.9
Nicotine	Period 1: Inhalation (N=6)	6	0.39	0.240	0.1	0.42	0.7
	Period 2: Mouth-holding (N=6)	6	0.21	0.194	0.0	0.16	0.6
	Period 3: Inhalation (N=6)	6	0.43	0.221	0.2	0.39	0.8
	Period 4: Mouth-holding (N=6)	6	0.17	0.119	0.1	0.14	0.4

Adverse Events

There were no adverse events associated with this trial.